Richard Girling

Office Phone:

(212) 380-2650


  Pro - Try 1 Week Free
 

    and access,

  •     75K PE/M&A Contacts
  •     +
  •     4.5K PE Firms
  •     3.6K M&A Advisors
  •     193K Transactions
  •     197K Companies

  •     Market Services
  •     Build Lists
  •     Research Sectors
  •     Uncover Opportunities

Bio

Richard Girling is one of Europe’s leading healthcare bankers with over 20 years of experience. Mr. Girling has advised on many of the largest healthcare transactions in Europe and Asia including: Sanofi-Synthelabo's $73 billion acquisition of Aventis, the $24 billion LBO of Alliance Boots plc, AstraZeneca in its $15 billion acquisition of MedImmune, Mayne Pharma's $2 billion sale to Hospira, Alliance Unichem in its $12 billion merger with Boots, CSL in its acquisition of Aventis Behring, and numerous transactions for Roche including the sale of its Vitamins division to DSM for $2 billion. Since the creation of the Healthcare practice at Centerview Partners, the Healthcare team has advised on a number of significant transactions including: Alliance Boots on its formation of a strategic partnership with Walgreens and its sale in a two-step $27bn transaction, the $4 billion sale of OSI to Astellas, the $3 billion acquisition of the real estate assets of Atria Senior Living Group by Ventas, the $722 million sale of Facet Biotech to Abbott Labs, the $500 million acquisition of a 46% stake in Stallergenes by Ares Life Sciences and the $112 million acquisition of Baxter’s Multisource injectable pharma business and the $153 million acquisition of a 94.1% interest in Promopharm by Hikma. Mr. Girling established Merrill Lynch’s European healthcare practice in 1998, and was Global Co-Head of Healthcare investment banking for the last six of those years. Following the acquisition by Bank of America, he was appointed the head of the merged Europe, Middle East and Asia (EMEA) and Asia-Pacific healthcare practices for the combined organization. Mr. Girling joined Merrill Lynch in 1998 from Salomon Brothers, where he worked from 1989 to 1998 and was head of the European Pharmaceutical and Healthcare team. Mr. Girling is a member of the Development Board, St Anne's College, Oxford University and is actively involved in supporting oncology research projects with Imperial College Trust, London. Mr. Girling holds a B.A. and M.A. degrees in Biochemistry from Oxford University.

Education